Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06161584 · ClinicalTrials.gov registry record
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
A clinical trial of Geographic Atrophy, sponsored by Apellis Pharmaceuticals.
- Active
- Registry status
- 300
- Enrollment target
- 20
- Study locations
NCT06161584: Active study of Geographic Atrophy, sponsored by Apellis Pharmaceuticals.
NCT06161584 is a study of Geographic Atrophy that is active but no longer recruiting, run by Apellis Pharmaceuticals. The registered enrollment target is 300 participants, above the 211-participant average among 27 other Geographic Atrophy trials with a reported enrollment target (42% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06161584, a study of Geographic Atrophy, is active but no longer recruiting, sponsored by Apellis Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
Conditions Studied
Interventions
- DRUG Pegcetacoplan
Study Locations (20)
California
- California Retina Consultants (01-026) - Bakersfield
- Retina-Vitreous Associates Medical Group (01-020) - Beverly Hills
- Illinois Retina Associates (01-035) - Fullerton
- Retinal Consultants Medical Group Inc (01-008) - Modesto
- Retina Consultants San Diego Inc. (01-018) - Poway
- California Retina Consultants (01-027) - Santa Barbara
- Bay Area Retina Associates (01-005) - Walnut Creek
Maryland
- The Retina Care Center (01-023) - Baltimore
- Cumberland Valley Retina Consultants, P.C. (01-002) - Hagerstown
- Mid Atlantic Retina Specialist (01-029) - Hagerstown
Georgia
- South East Retina Center, PC (01-030) - Augusta
- Georgia Retina (01-032) - Marietta
New Jersey
- Mid Atlantic Retina Research (01-014) - Cherry Hill
- Mid Atlantic Retina (01-031) - Cherry Hill
New York
- OCLI Research Department (01-007) - Oceanside
- Long Island Vitreoretinal Consultants (01-013) - Westbury
Colorado
- Colorado Retina Associates, PLLC (01-011) - Lakewood
Florida
- Retina Specialty Institute (01-019) - Pensacola
Illinois
- Illinois Retina Associates (01-037) - Oak Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2023-09-28 |
| Est. Completion | 2027-06 |
What the registry record for NCT06161584 still lists
NCT06161584 is an observational study that tracks outcomes without assigning an intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, above the 211-participant average among 27 other Geographic Atrophy trials with a reported enrollment target (42% higher).
The record links to 1 condition, with Geographic Atrophy appearing as the primary indexed condition, and to 1 intervention - of which Pegcetacoplan is the first listed.
NCT06161584 names 20 study sites across 9 states, led by California, Maryland, Georgia.
Frequently Asked Questions
What is clinical trial NCT06161584 about?
NCT06161584 is a clinical study titled "A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration". A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
What is the current status of trial NCT06161584?
This trial is currently active not recruiting. The enrollment target is 300 participants. The study started on 2023-09-28. Estimated completion is 2027-06.
What conditions does trial NCT06161584 study?
This clinical trial studies the following conditions: Geographic Atrophy.
What interventions are being tested in trial NCT06161584?
The interventions under investigation include: Pegcetacoplan (DRUG).
Who is sponsoring clinical trial NCT06161584?
This trial is sponsored by Apellis Pharmaceuticals, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06161584 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Geographic Atrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06161584's enrollment target sits among peer trials
300 6th of 27 higher than 22 of 27 other Geographic Atrophy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Geographic Atrophy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration
RECRUITING · Phase 1
-
High Resolution Retinal Imaging
RECRUITING
-
SGLT2 Inhibitors in Geographic Atrophy
RECRUITING · Phase 2
-
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
RECRUITING · Phase 2
-
A Phase IIb Randomized, Multicenter Trial of Subretinal CPCB-RPE1 in Advanced Dry AMD (Geographic Atrophy)
RECRUITING · Phase 2
-
Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI